New targeted treatments in lung cancer - Overview of clinical trials

Lung Cancer

Volumn 45, Issue SUPPL. 2, 2004, Pages

  Korfee, S ^a   Gauler, T ^a   Hepp, R ^a   Pottgen C ^b   Eberhardt, W ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HOSPITAL PADRE HURTADO   (Chile)

Author keywords

Clinical trials; EGF R; Lung cancer; Molecular targeted therapy; VEGF R

Indexed keywords

ANTIBODY; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CISPLATIN DERIVATIVE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; GEFITINIB; IMATINIB; ISIS 3521; MATUZUMAB; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NEW DRUG; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SCH 63668; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VINCRISTINE;

ADVANCED CANCER; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULE; PRIORITY JOURNAL; PROTEIN FAMILY; REGISTER; SOLID TUMOR; STANDARD; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TARGET CELL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS;

EID: 8444239438     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.07.974     Document Type: Conference Paper

References (57)

1. Parkin D.M. Global cancer statistics in the year 2000 Lancet Oncol 2 9 2001 533 543
2. Ginsberg R.J., Vokes E.E., and Rosenzweig K. Non-small cell lung cancer DeVita V.T. Hellmann S. Rosenberg S.A. 6th edition Cancer: Principles and Practice of Oncology Vol. 1 2001 925 983
3. Schiller J.H., Harrington D., and Belani C.P. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 2002 92 98
4. Hanahan D., and Weinberg R.A. The hallmarks of cancer Cell 100 1 2000 57 70
5. Vogel C.L., and Franco S.X. Clinical experience with trastuzumab (herceptin) Breast J 9 6 2003 452 462
6. Talpaz M., Silver R.T., and Druker B.J. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937
7. van Oosterom A.T., Judson I.R., and Verweij J. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 2002 83 87
8. Ho P.T., and Parkinson D.R. Antisense oligonucleotides as therapeutics for malignant diseases Semin Oncol 24 1997 187 202
9. Smalley W., Ray W.A., Daugherty J., and Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study Arch Intern Med 159 1999 161 166
10. www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD-search&DB-pubmed
11. Gridelli C., Rossi A., and Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents Oncogene 22 42 2003 6629 6638
12. Cooke T., Reeves J., Lanigan A., and Stanton P. HER2 as a prognostic and predictive marker for breast cancer Ann Oncol 12 Suppl 1 2001 S23 S28
13. Slamon D.J., Leyland-Jones B., and Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 2001 783 792
14. Lal P., Salazar P.A., and Hudis C.A. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring Am J Clin Pathol 121 5 2004 631 636
15. Langer C.J., Stephenson P., and Thor A. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598 J Clin Oncol 22 7 2004 1180 1187
16. Zinner R.G., Glisson B.S., and Pisters K.M. Cisplatin and Gemcitabine combined with Herceptin in patients (Pts) with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC). A phase II trial Proc Am Soc Clin Oncol 19 2001 328a
17. Ullrich A., Coussens L., and Hayflick J.S. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells Nature 309 5967 1984 418 425
18. Kelly K., Hanna N., and Rosenberg N. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV nonsmall cell lung cancer Proc Am Soc Clin Oncol 22 2003 644
19. Gatzemeier U., Rosell R., and Ramlau R. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 642
20. Kim E.S., Mauer A.M., and Tran H.T. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) Mocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report Proc Am Soc Clin Oncol 22 2003 642
21. Robert F., Blumenschein G., and Dicke J. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 643
22. Kollmannsberger C., Schittenhelm M., and Honecker F. Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): A phase-I study Proc Am Soc Clin Oncol 22 2003 627
23. Figlin R.A., Bellegrun A.S., and Crawford J. Abx-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results Proc Am Soc Clin Oncol 21 2002 10a
24. Ranson M., Hammond L.A., and Ferry D. ZD1839 a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 9 2002 2240 2250
25. Kris M.G., Natale R.B., and Herbst R.S. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial J Am Med Assoc 290 16 2003 2149 2158
26. Fukuoka M., Yano S., and Giaccone G. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 12 2003 2237 2246
27. Giaccone G., Herbst R.S., and Manegold C. Gefitinib in combination with gemcitabine and cisplatin in advanced nonsmall-cell lung cancer: a phase III trial -- INTACT 1 J Clin Oncol 22 5 2004 777 784
28. Herbst R.S., Giaccone G., and Schiller J.H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial -- INTACT 2 J Clin Oncol 22 5 2004 785 794
29. Perez-Soler R., Chachoa A., and Hubermann M. Final results from a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non small cell lung cancer following failure of platinum based chemotherapy Lung Cancer 41 2003 246
30. Patel J., Miller D.A., and Kris G.M. Encouraging activity and durable responses demonstrated by the Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced Bronchioloalveoldr (BAC) Cell Carcinoma Lung Cancer 41 2003 56
31. Sandier A.B., Mininberg E., and Henderson T. A phase I/II study of the anti-VEGF Mab bevacizumab (Avastin) and erlotinib (Tarceva), a Her1/EGFR-TK inhibitor: a multifaceted approach for the treatment of recurrent non-small cell lung cancer Lung Cancer 41 2003 36
32. Mauer A., Haraf D., and Hoffman P.C. A phase I study of OSI-774 in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2003 651
33. Davies A.M., Hesketh P.J., and Lara P.N. OSI-774 and vinorelbine in advanced solid tumors (with emphasis on nonsmall cell lung cancer, NSCLC): A phase I study Proc Am Soc Clin Oncol 22 2003 249
34. Herbst R.S., Prage D., and Hermann V. TRIBUTE -- A phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 23 2004 617
35. Gatzemeier U., Pluzanska A., and Szczesna A. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer Proc Am Soc Clin Oncol 23 2004 617
36. Garrison M., Tolcher A., and McCreery H. A phase 1 and pharmacokinetic study of CI-1033, a Pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors Proc Am Soc Clin Oncol 20 2001 283
37. Hidalgo M., Erlichman C., and Rawinsky E.K. Phase I trial of EKB-549, an irreversible inhibitor of the epidermal growth factor (EGFR) in patients with advanced solid tumors Proc Am Soc Clin Oncol 21 2002 17a
38. Dumez H., Hoekstra R., and Eskens F. A phase I and pharmacologic study of PKI epidermal 166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered 3 times a week to patients with advanced cancer Proc Am Soc Clin Oncol 21 2002 86a
39. Potti A., Moazzam N., and Ramar K. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma Ann Oncol 14 6 2003 894 897
40. Johnson B.E., Fisher B., and Fisher T. Phase II study of STI 571 (Gleevec) for patients with small cell lung cancer Proc Am Soc Clin Oncol 21 2002 393a
41. DeVore R., Fehrenbacher R.S., and Herbst R.S. A randomized phase II trial comparing rhuMAB VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin paclitaxel (CP) to CP alone in patients with stage III/IV NSCLC Proc Am Soc Clin Oncol 19 2000 485a
42. Johnson D.H., DeVore R., and Kabbinavar F. Carboplatin (C) + Paclitaxel (T) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer Proc Am Soc Clin Oncol 20 2001 315a
43. Minami H., Ebi H., and Tahara M. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors Proc Am Soc Clin Oncol 22 2003 194
44. Basser R., Hurwitz R., and Barge A. Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors Proc Am Soc Clin Oncol 20 2001 100a
45. Rosen L., Mulay M., and Mayers A. Phase I dose escalating trial of SU 5416, a novel angiogenesis inhibitor in patients with advanced malignancies Proc Am Soc Clin Oncol 18 1999 161a
46. Kuenen B.C., Rosen L., and Smit E. Dose finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 6 2002 1657 1667
47. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development J Clin Oncol 17 11 1999 3631 3652
48. Abstract Kim E.S., Kies M.S., and Fossela F.V. A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxane refractory/resistant patients with non small cell lung cancer (NSCLC): final report Proc Ann Meeting Am Assoc Cancer Res 43 2002 2375
49. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation Nature 334 6184 1988 661 665
50. Yuen A., Halsey J., and Fisher G. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer Proc Am Soc Clin Oncol 20 2001 309a
51. Lynch R., Raju M., and Lind A. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report Proc Am Soc Clin Oncol 22 2003 623
52. Shepherd F.A., Giaccone G., and Seymour L. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-Line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada -- Clinical Trials Group and the European Organization for Research and Treatment of Cancer J Clin OncoL 20 22 2002 4434 4439
53. Smylie M., Mercier R., and Aboulafia D. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 20 2001 307a
54. Rudin C., Ottreson A.O., and George C.M. A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer Proc Am Soc Clin Oncol 20 2001 322a
55. Gadgeel S.M., Thatai L., and Kraut M. Phase II study of celecoxib and docetaxe in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy Proc Am Soc Clin Oncol 22 2003 684
56. Altorki N., Keresztes R.S., and Port J.L. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer Proc Am Soc Clin Oncol 21 2002 26a
57. Momparler R.L., and Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer Lung Cancer 34 2001 5111 5115